News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure completes successful Secondary Public Offering of approximately USD 12 million with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies
19 July 2023
Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule OATD-01, taking another important step in the development of this program.
3 July 2023
Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarcoidosis study
22 June 2023
Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress
30 March 2023
Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer
8 March 2023